Core Viewpoint - Eli Lilly's innovative drug Tirzepatide has been officially included in the new national medical insurance directory, leading to a new round of price reductions in the domestic diabetes and weight loss drug market [1] Group 1: Market Impact - The inclusion of Tirzepatide in the medical insurance directory has prompted some online pharmaceutical platforms to initiate pre-sale price reductions ahead of the official price drop [1] - On Meituan Buy Medicine, the pre-sale price for Tirzepatide 10mg has dropped to as low as 450 yuan, which is approximately 20% of the previous price [1] - Other GLP-1 drugs, such as Semaglutide, have also seen varying degrees of price adjustments online, indicating a gradual transmission effect of the insurance policy on the outpatient market prices [1]